Smith & Nephew shares fall on U.S. knee implant decline
Updated
Updated · MarketWatch · May 6
Smith & Nephew shares fall on U.S. knee implant decline
13 articles · Updated · MarketWatch · May 6
The stock dropped 2% to £11.365 after first-quarter U.S. Knee Implants fell 10.3%, while quarterly revenue rose to $1.50 billion from $1.40 billion.
Orthopedics underlying growth was 0.8%, below analysts' 2.2% expectation, as weakness in U.S. knees and Trauma & Extremities partly offset strength in sports medicine.
The company also launched a $500 million buyback, about 3.5% of market value, but RBC said the results did not materially reduce potential downside risk to 2026 guidance.
Despite a $500M buyback, why do analysts fear Smith & Nephew’s future guidance is still at risk in a growing market?
With Medicare cutting payments to its customers, can Smith & Nephew's new technology overcome the financial squeeze on US hospitals?
Is a planned product launch a valid reason for a 10% sales drop, or a sign of deeper competitive struggles?